Vistagen Therapeutics Financials - Benzinga

Vistagen Therapeutics Inc

VTGNNASDAQ

Trade with Public

Trade with Public

$0.2730

-0.022-7.46%

al cierre: Sep 25, 5:00 PM EST

$0.2620

-0.011-4.03%

After hour: Sep 25, 7:57 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Vistagen Therapeutics Financials

Vistagen Therapeutics (VTGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share

Benzinga Newsdesk

PRO
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per

Benzinga Newsdesk

Vistagen Therapeutics Earnings Report: Q3 Overview

Benzinga Insights

PRO
VistaGen Therapeutics Q3 EPS $(0.45) Misses $(0.44) Estimate, Sales $303.000K Miss $366.000K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.44) by 2.74 percent. This is a 2.17 percent increase over losses of $(0.46) per share

Benzinga Newsdesk

Earnings Scheduled For February 12, 2026

Benzinga Insights

Crude Oil Rises Over 1%; General Mills Earnings Top Views

Avi Kapoor

© 2026 Benzinga | All Rights Reserved